DrugPatentWatch Database Preview

Sb Pharmco Company Profile

« Back to Dashboard

What is the competitive landscape for SB PHARMCO, and what generic alternatives to SB PHARMCO drugs are available?

SB PHARMCO has three approved drugs.

There are two US patents protecting SB PHARMCO drugs.

There are one hundred and ten patent family members on SB PHARMCO drugs in forty-six countries and fifty-six supplementary protection certificates in fourteen countries.

Summary for Sb Pharmco

International Patents:	110
US Patents:	2
Tradenames:	3
Ingredients:	3
NDAs:	3

Drugs and US Patents for Sb Pharmco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002		DISCN	Yes	No	8,236,345		Y
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-003	Oct 10, 2002		DISCN	Yes	No	8,236,345		Y
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-003	May 25, 1999		RX	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-005	Aug 25, 2003		DISCN	Yes	No	8,236,345		Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-001	Nov 23, 2005		DISCN	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999		RX	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-005	Mar 30, 2007		DISCN	Yes	No	7,358,366*PED				Y

Expired US Patents for Sb Pharmco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-004	May 25, 1999	6,288,095*PED
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002	5,965,584*PED
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-003	Oct 10, 2002	6,288,095*PED
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-005	Mar 30, 2007	5,002,953*PED
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-003	May 25, 1999	7,358,366*PED
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-002	Nov 23, 2005	7,358,366*PED
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-004	Aug 25, 2003	5,002,953*PED

Paragraph IV (Patent) Challenges for SB PHARMCO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1 mg/4 mg, 2 mg/4 mg and 4 mg/4 mg		2006-12-22
	Tablets	1 mg/ 500 mg, 2 mg/ 500mg, 4 mg/ 500 mg, 2 mg/ 1000 mg and 4 mg/ 1000 mg		2004-10-22
	Tablets	8 mg/2 mg and 8 mg/4 mg		2008-05-30

International Patents for Sb Pharmco Drugs

Country	Patent Number	Estimated Expiration
Croatia	P20010774
Malaysia	125516
Australia	2755102
African Regional IP Organization (ARIPO)	1389
Yugoslavia	38802
Bulgaria	65616
European Patent Office	1231918

Supplementary Protection Certificates for Sb Pharmco Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261586	C300524	Netherlands		PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
0658161	SPC/GB01/003	United Kingdom		PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
2498758	LUC00152	Luxembourg		PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
0658161	39/2000	Austria		PRODUCT NAME: ROSIGLITAZONE MALEAT; NAT. REGISTRATION NO/DATE: EU/1/00/137/001 - EU/1/00/137/012 20000711; FIRST REGISTRATION: LI 55176 19990929
1412357	DO 77; 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
0306228	38/2000	Austria		PRODUCT NAME: ROSIGLITAZONE; NAT. REGISTRATION NO/DATE: EU/1/00/137/001 - EU/1/00/137/012 20000711; FIRST REGISTRATION: LI 55176 19990929
2498758	CA 2020 00017	Denmark		PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sb Pharmco